DrugPatentWatch Database Preview

Glaxosmithkline Cons Company Profile

Email this page to a colleague

GLAXOSMITHKLINE CONS has fourteen approved drugs.

There are ten US patents protecting GLAXOSMITHKLINE CONS drugs.

There are two hundred and eighty-three patent family members on GLAXOSMITHKLINE CONS drugs in forty-three countries and twenty-one supplementary protection certificates in fourteen countries.

International Patents:	283
US Patents:	10
Tradenames:	10
Ingredients:	9
NDAs:	14
PTAB Cases with Glaxosmithkline Cons as petitioner:	See PTAB cases with Glaxosmithkline Cons as petitioner

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline Cons	VOLTAREN	diclofenac sodium	GEL;TOPICAL	022122-001	Oct 17, 2007	AB	RX	Yes	Yes		Start Trial				Start Trial
Glaxosmithkline Cons	FLONASE SENSIMIST ALLERGY RELIEF	fluticasone furoate	SPRAY, METERED;NASAL	022051-002	Aug 2, 2016		OTC	Yes	Yes	8,347,879	Start Trial	Y			Start Trial
Glaxosmithkline Cons	LAMISIL AT	terbinafine hydrochloride	SOLUTION;TOPICAL	021124-001	Mar 17, 2000		OTC	Yes	Yes		Start Trial				Start Trial
Glaxosmithkline Cons	FLONASE SENSIMIST ALLERGY RELIEF	fluticasone furoate	SPRAY, METERED;NASAL	022051-002	Aug 2, 2016		OTC	Yes	Yes	8,062,264	Start Trial	Y			Start Trial
Glaxosmithkline Cons	LAMISIL	terbinafine	GEL;TOPICAL	020846-001	Apr 29, 1998		DISCN	No	No		Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline Cons	NICORETTE	nicotine polacrilex	TROCHE/LOZENGE;ORAL	021330-002	Oct 31, 2002	5,110,605	Start Trial
Glaxosmithkline Cons	LAMISIL AT	terbinafine	GEL;TOPICAL	021958-001	Jul 24, 2006	5,681,849*PED	Start Trial
Glaxosmithkline Cons	LAMISIL AT	terbinafine hydrochloride	SOLUTION;TOPICAL	021124-001	Mar 17, 2000	4,680,291	Start Trial
Glaxosmithkline Cons	EXCEDRIN (MIGRAINE)	acetaminophen; aspirin; caffeine	TABLET;ORAL	020802-001	Jan 14, 1998	5,972,916	Start Trial
Glaxosmithkline Cons	ALLI	orlistat	CAPSULE;ORAL	021887-001	Feb 7, 2007	4,598,089	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Gum	2 mg	➤ Subscribe	2013-01-22
➤ Subscribe	Capsules	60 mg	➤ Subscribe	2010-09-08
➤ Subscribe	Gum	4 mg	➤ Subscribe	2013-01-22

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1305329	91429	Luxembourg	Start Trial	91429, EXPIRES: 20230111
1305329	122008000029	Germany	Start Trial	PRODUCT NAME: FLUTICASONFUROAT UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/07/434/001-003 20080111
1305329	08C0014	France	Start Trial	PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
1305329	SZ 12/2008	Austria	Start Trial	PRODUCT NAME: FLUTICASON FUROAT UND DESSEN SOLVATE
0129748	98C0042	Belgium	Start Trial	PRODUCT NAME: ORLISTAT; REGISTRATION NO/DATE: EU/1/98/071/001 19980729
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.